Research programme: cognitive disorders therapeutics - Targacept/AstraZeneca
Latest Information Update: 07 Mar 2013
At a glance
- Originator Targacept
- Developer AstraZeneca; Targacept
- Mechanism of Action Alpha4 beta2 nicotinic receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cognition disorders